Moneycontrol PRO

Anubhav Sahu

Principal Analyst

Moneycontrol Research

Reliance Industries Q3FY22: Retail, renewables emerging as key growth anchors

MONEYCONTROL-RESEARCH

Reliance Industries Q3FY22: Retail, renewables emerging as key growth anchors

Retail and digital assets are moving from strength to strength in terms of capabilities through inorganic forays, indicating that RIL would be in a vantage position to capitalize on new age businesses and normalization of consumption demand in times to come

Bhansali Engineering: Margins likely to moderate further; valuation fair

BUSINESS

Bhansali Engineering: Margins likely to moderate further; valuation fair

Bhansali looks to step up the overall ABS capacity to 200,000 tonnes from the current 137,000 tonnes, with a capex of Rs 500 crore

Hikal: Why we are closing recommendation for this stock

BUSINESS

Hikal: Why we are closing recommendation for this stock

Environmental compliance, particularly for chemicals and pharma industry, is sacrosanct. Taking that into account, we close our Outperform rating for Hikal and would prefer to stay on the sidelines

Divi’s Lab: Green chemistry can set it apart

BUSINESS

Divi’s Lab: Green chemistry can set it apart

The management of Divi's Lab asserts that there are no Nitrosamine or Azido impurities in the company's Sartan API offerings.

Laurus Labs: Pick-up in fermentation opportunity a key watch

BUSINESS

Laurus Labs: Pick-up in fermentation opportunity a key watch

As per a recent presentation by chief business officer, Laurus Bio, Rajesh Krishnamurthy, for most of the cultivated meat manufacturers, about two-thirds of the variable cost is triggered by proteins and protein growth factors. And Laurus plans to reduce its cost through economies of scale and process innovation.

At Shivalik Rasayan, pharma comes up as a big growth lever

BUSINESS

At Shivalik Rasayan, pharma comes up as a big growth lever

Medicamen Biotech plans to go for domestic launch of oncology formulations from January 2022, in sync with API supply from Shivalik Rasayan. This is the key near-term trigger.

Supriya Lifescience IPO: A play on lower supply-chain risk for APIs

BUSINESS

Supriya Lifescience IPO: A play on lower supply-chain risk for APIs

Supriya Lifescience's key strengths include 12 products, contributing to 67 percent of sales, which are backward integrated to the level of basic chemicals

Fed presses the pedal harder on taper on stronger growth

BUSINESS

Fed presses the pedal harder on taper on stronger growth

Fed chair Jerome Powell indicated that the time between the end of tapering and the first rate hike could be short. Interestingly, the rationale for that has less to do with inflation, but more to do with the strong demand environment and labour market tightness

Medplus Health Services IPO: What does the investment prescription read?

BUSINESS

Medplus Health Services IPO: What does the investment prescription read?

Investors can wait for traction in operational performance post the listing before taking a call on investment in Medplus Health Services

Galaxy Surfactants looks forward to life beyond cost inflation

BUSINESS

Galaxy Surfactants looks forward to life beyond cost inflation

Operationalisation of new plants and the overall capacity utilisation of 67 percent provide enough room to meet medium-term demand for Galaxy Surfactants

IPCA Labs: Domestic beat offsets API weakness

BUSINESS

IPCA Labs: Domestic beat offsets API weakness

The key near-term challenge for IPCA is with respect to API sales. The company expects a softer Q3 due to the supply disruption in Sartan APIs and elevated raw material prices

Explained, the US earnings season

BUSINESS

Explained, the US earnings season

In 2021, earnings have accounted for the lion’s share of S&P 500's total return

Tarsons Products IPO: A play on rapid growth in health care research

BUSINESS

Tarsons Products IPO: A play on rapid growth in health care research

Going forward, research demand in Contract Research Organisations, IVF clinics and diagnostic labs is expected to lead the overall demand for Tarsons Products

Navin Fluorine: Executing multi-year contract template

BUSINESS

Navin Fluorine: Executing multi-year contract template

Navin Fluorine's recent success on new molecule/product launches stems from its in-house R&D at the Surat facility. This new deal is one of them

Vidhi Specialty: Is the margin contraction a worry for the long term?

BUSINESS

Vidhi Specialty: Is the margin contraction a worry for the long term?

We continue to look at Vidhi as the preferred way to play the food colour theme because of its improved operational metrics

Fed tapers, but no tantrum

BUSINESS

Fed tapers, but no tantrum

While the “tapering” is steeper than earlier cycle of 2014, Jerome Powell emphasized its need, given that inflation this time is much higher, job openings are better and “demand is very, very strong”.

Sun Pharma: Fully valued, though performance impressive

BUSINESS

Sun Pharma: Fully valued, though performance impressive

Sales of specialty products during the reporting quarter clocked $157 million against $148 million in Q1FY22 and $108 million in Q2FY21.

Laurus Labs: New growth levers taking shape

BUSINESS

Laurus Labs: New growth levers taking shape

The businesses to track for Laurus Labs, as far as future growth trajectory is concerned, are that of synthesis and biotech

Cadila: Unfolding vaccine opportunity can offset US headwinds

BUSINESS

Cadila: Unfolding vaccine opportunity can offset US headwinds

For a longer term play, Cadila has a promising pipeline for NCEs (New chemical entities), biosimilars and injectables

Dr Reddy’s: Aced by emerging markets' growth

BUSINESS

Dr Reddy’s: Aced by emerging markets' growth

While DRL is hit by pricing erosion in the US business, potential growth in the limited competition products underlines a positive outlook

Lupin: Competitive pressure remains in the US market

BUSINESS

Lupin: Competitive pressure remains in the US market

Lupin guided for 16 percent EBITDA margin in H1 of FY22. While sequentially it indicates normalisation, given the elevated pricing pressure in the US market, execution will be closely monitored

Hikal: 'China plus' opportunity adds to conviction for capex

BUSINESS

Hikal: 'China plus' opportunity adds to conviction for capex

For FY21 and FY22, Hikal is spending close to Rs 600 crore in capacity enhancement, where the major part of the benefit will accrue in FY24

SRF: Inflation can impact capex payback period

BUSINESS

SRF: Inflation can impact capex payback period

For FY22, SRF's capex allocation stands at Rs 1,500-1,800 crore. The capex spent so far is nearly Rs 600 crore, which is expected to go up in H2

Cipla: Focus shifts to FY23 launches

BUSINESS

Cipla: Focus shifts to FY23 launches

In the US market, while the Albuterol opportunity is stabilising for Cipla, traction for Arformoterol and the high-value product launch calendar in H2 FY23 is a key watch

Sections
ISO 27001 - BSI Assurance Mark